NICE Recommends NHS Funding for Bridge to Life's Liver Perfusion System
Event summary
- NICE issued guidance on August 20, 2026, recommending routine NHS funding for Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System.
- NICE found that advanced perfusion systems like VitaSmart™ offer clinical and financial benefits over traditional static cold storage, including improved graft survival and fewer biliary complications.
- VitaSmart™ is designed for operational simplicity, ease of adoption, and capital efficiency, integrating seamlessly into clinical workflows.
- The system is available in the U.S., U.K., Europe, Saudi Arabia, India, and all countries accepting the CE mark.
The big picture
NICE's recommendation solidifies hypothermic oxygenated perfusion as a standard of care in liver transplantation, aligning with broader trends toward advanced organ preservation technologies. Bridge to Life's VitaSmart™ system is positioned to benefit from this shift, particularly as healthcare systems seek to improve graft outcomes and operational efficiency. The company's differentiated portfolio, spanning both static and machine perfusion solutions, strengthens its competitive position in the global organ preservation market.
What we're watching
- Adoption Pace
- The pace at which NHS hospitals adopt the VitaSmart™ system following NICE's recommendation.
- U.S. Market Penetration
- How Bridge to Life will leverage FDA De Novo clearance to expand VitaSmart™ adoption in the U.S.
- Competitive Dynamics
- Whether Bridge to Life can maintain its market lead in hypothermic oxygenated perfusion against potential competitors.